Skip to main content
Equibles
EMMA logo

EMMA · Emmaus Life Sciences, Inc. · Metrics

Track EMMA — free

Use EMMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EMMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.03 +0.01 (+22.99%) At close · Aug 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the Company's existing cash balance and anticipated cash flows cannot satisfy its current debt and ongoing obligations, combined with the uncommitted nature of the Company's financing plans, there is substantial doubt about the Company’s ability to continue as a going concern for 12 months from the date that these condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$2.25M
Shares
70.19M
Volume · Aug 21 847.1K Avg daily vol (3M) 157.21K

EMMA metrics

73 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.03
Market cap
$2.25M

Price action

20 metrics
Price change (1W)
+179.1%
Price change (30D)
—
Price change (3M)
+230.9%
Price change (6M)
+129.3%
Price change (YTD)
+146.9%
Price change (1Y)
+169.7%
Trailing year
Price change (5Y)
—
52-week high
$0.03
52-week low
$0.01
Change from 52-week high
+0.0%
Change from 52-week low
+282.1%
Annualized volatility
197.4%
Annualized volatility (3M)
—
Beta
-0.9
RSI (14D)
89.5
Price vs SMA 50
+179.8%
Price vs SMA 200
+163.5%
Avg volume (3M)
157,210
Relative volume
5.4
Average dollar volume
$2,703

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
70.19M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.6×
reciprocal yield 63.6%
EV / EBITDA
5.3×
reciprocal yield 18.9%
EV / EBIT
5.4×
reciprocal yield 18.6%
P / sales
0.1×
reciprocal yield 689.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
0.6
reciprocal yield 176.1%
Earnings yield
-267.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.7×
reciprocal yield 58.2%
EV / revenue historical average (5Y)
2.3×
reciprocal yield 44.1%
EV / EBIT historical average (3Y)
346.9×
reciprocal yield 0.3%
EV / EBIT historical average (5Y)
346.9×
reciprocal yield 0.3%
EV / EBITDA historical average (3Y)
109.7×
reciprocal yield 0.9%
EV / EBITDA historical average (5Y)
109.7×
reciprocal yield 0.9%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
93.6%
Operating margin
29.3%
Trailing 12 months
Net margin
-38.8%
Gross profit (TTM)
$14.54M
Operating profit (TTM)
$4.55M
Net income (TTM)
−$6.02M
Trailing 12 months
Diluted EPS (TTM)
$-0.09
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.19
Gross profit per diluted share (TTM)
$0.18
Operating profit per diluted share (TTM)
$0.04
EBITDA per diluted share (TTM)
$0.05
Net income per diluted share (TTM)
$-0.10
Operating cash flow per diluted share (TTM)
$0.05
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.91

Growth

11 metrics
Revenue growth YoY
+124.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$15.53M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+88.7%
Year over year · more shares
Revenue CAGR (3Y)
-12.2%
Revenue CAGR (5Y)
-11.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-36.8%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
$4.61M
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
0.6
Net debt / EBITDA
4.8
Return on invested capital
—
Trailing 12 months
Net cash
−$22.18M
Latest balance sheet
Cash & equivalents
$2.81M
Total assets
$16.37M
Total debt
$24.99M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$3.97M
Capital expenditures (TTM)
$2,000
R&D (TTM)
$237,000
SG&A (TTM)
—
Stock compensation (TTM)
$17,000
R&D / revenue
1.5%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
$15,026
Insider-sentiment score
81 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 822370 CUSIP 29137T101 Visit website Investor relations